Key statistics
On Friday, Immunitybio Inc (IBRX:NSQ) closed at 5.57, 109.01% above the 52 week low of 2.67 set on Nov 10, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 5.25 |
---|---|
High | 5.58 |
Low | 5.14 |
Bid | 5.53 |
Offer | 5.57 |
Previous close | 5.30 |
Average volume | 9.37m |
---|---|
Shares outstanding | 696.53m |
Free float | 159.61m |
P/E (TTM) | -- |
Market cap | 3.88bn USD |
EPS (TTM) | -0.9356 USD |
Data delayed at least 15 minutes, as of Nov 08 2024 21:00 GMT.
More ▼
- First Patients Dosed in Phase 1 Clinical Study of ImmunityBio’s CAR-NK Cell Therapy for the Treatment of Relapsed B-Cell Non-Hodgkin Lymphoma
- ImmunityBio to Participate in the Jefferies London Healthcare Conference
- ImmunityBio Presents Positive Long-Term Overall Survival Data in Non-Small Cell Lung Cancer Patients and Announces Registrational Intent Phase 3 Trials with ANKTIVA® and Checkpoint Immunotherapy at World Conference on Lung Cancer
- ImmunityBio’s ANKTIVA® Now Covered By More Than a Dozen Insurance Plans Representing Over 100 Million Lives Within Months of FDA Approval